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Abstract
The aim of the present study was to evaluate the effect of cystic fibrosis and antibiotic therapy
on intestinal microbiota composition and intestinal inflammation in children and adolescents. A
cross-sectional controlled study was conducted with 36 children and adolescents: 19 in the
cystic fibrosis group (CFG) and 17 in the control group (CG) matched for age and sex. The
CFG was subdivided based on the use of antibiotic therapy (CFAB group) and non-use of anti-
biotic therapy (CFnAB group). The following data were evaluated: colonization, antibiotic ther-
apy, mutation, breastfeeding, use of infant formula, type of delivery, introduction of solid foods,
body mass index, fecal calprotectin and intestinal microbiota composition (fluorescence in situ
hybridization). Intestinal inflammation evaluated by fecal calprotectin was significantly higher
in the CFG (median: 40.80 µg/g, IQR: 19.80–87.10, p = 0.040) and CFAB group (median:
62.95 µg/g, IQR: 21.80–136.62, p = 0.045) compared to the CG (median: 20.15 µg/g, IQR:
16.20–31.00), and the Bacteroides, Firmicutes, Eubacterium rectale and Faecalibacterium
prausnitzii were significantly decreased (p < 0.05) in the CFG compared to the CG, whereas
the bacteria Clostridium difficile, Escherichia coli and Pseudomonas aeruginosa were signifi-
cantly increased in the CFG (p < 0.05). The main differences were found between the CG and
CFAB group for Eubacterium rectale (p = 0.006), Bifidobacterium (p = 0.017), Escherichia coli
(p = 0.030), Firmicutes (p = 0.002), Pseudomonas aeruginosa (p < 0.001) and Clostridium diffi-
cile (p = 0.006). The results of this study confirm intestinal inflammation in patients with CF,
which may be related to changes in the composition of the intestinal microbiota.
Introduction
Microbiome acquisition begins in the uterus and progresses during childhood. The composi-
tion of the microbiota is influenced by the type of delivery, feeding, exposure to antibiotics in
the perinatal period and maternal physical contact [1, 2]. An increase in the diversity of the
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intestinal microbiota occurs beginning at birth and children one to three years of age have a
pattern similar to that found in adults. However, the occurrence of infection results in a lower
diversity of microbiota [3, 4]. In addition to being associated with health promotion, breast
milk provides significant amounts of Bifidobacterium and Lactobacillus [5] and the ingestion
of solid foods may or may not exert a positive influence on the microbiome, depending on the
type of food [6].
The defect in the cystic fibrosis transmembrane regulator in patients with cystic fibrosis
(CF) can have manifestations in the gastrointestinal tract, such as gastroesophageal reflux, vis-
cous intestinal mucus due to dehydration, acidification of the medium, altered mucosal glyco-
sylation [7], distal intestinal obstruction, inflammation, bacterial overgrowth in the small
intestine, slow transit time, inflammatory bowel disease [8] and dysbiosis [9], the latter of
which can trigger the overgrowth of opportunistic pathogens and contribute to the develop-
ment of diseases [10, 11].
The mechanism underlying the inflammatory bowel process remains unclear, but inflammation
in evidenced by the increase in inflammatory markers, such as calprotectin and rectal nitric oxide,
in patients with CF [6, 12]. The use of antibiotics, such as tobramycin and erythromycin, is another
factor that may influence the microbiota of the gastrointestinal tract [11]. While the ecological bal-
ance is normally restored within a few weeks after antibiotic ingestion, there is evidence that antibi-
otic-associated disorders may persist for a long time after treatment. Thus, prolonged exposure to
antibiotics may result in the overgrowth of antibiotic-resistant bacteria [13], as Clostridium difficile
(C. difficile), which can cause severe diarrhea and/or pseudomembranous colitis [14].
Studies have shown that patients with CF typically have decreased amounts of Bifidobacter-
ium spp. [6], the Bacteroides-Prevotella group [12], Clostridium cluster XIVa [15], Faecalibac-
terium prausnitzii (F. prausnitzii) [6] and Eubacterium rectale (E. rectale) [6], whereas
Enterobacteriaceae and Clostridia [14] are increased.
The clinical relevance of the change in intestinal microorganisms is not well established,
but the microflora of the gastrointestinal tract is known to be related to metabolic functions,
such as the regulation of host immune response. Thus, the frequent use of antibiotics can have
a negative cumulative effect on the metabolism and immune system in this population [16].
The aim of the present study was to evaluate the effect of CF and antibiotic therapy on intes-
tinal microbiota composition and intestinal inflammation in children and adolescents.
Methods and subjects
Study design
A cross-sectional study was conducted between March and December 2016 at the Joana de
Gusmão Children’s Hospital in the city of Floriano´polis, Brazil. This study received approval
from the Human Research Ethics Committees of the hospital and the Federal University of
Santa Catarina (certificate number: 48959715.2.1001.0121). The legal guardians of the children
and adolescents signed a statement of informed consent.
Subjects
The required sample size calculated by the difference in means was 18 for each group (OpenEpi1
program, 1:1 proportion of exposed to non-exposed, 80% power and 95% confidence level).
Thus, the overall sample was composed of 36 children and adolescents. The control group (CG)
was composed of 17 individuals with a median age of 3.00 years [interquartile range (IQR): 0.60–
7.00 years] and cystic fibrosis group (CFG) was composed of 19 individuals with a median age of
4.00 years (IQR: 1.10–9.50 years). Moreover, the CFG was subdivided based on the use of antibi-
otic therapy (CFAB group) and non-use of antibiotic therapy (CFnAB group).
Intestinal microbiota composition in patients with cystic fibrosis
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The inclusion criteria for the CFG were a diagnosis of CF (chloride sweat test 60 mmol/L)
and clinical stability for at least 30 days prior to the data collection process [17]. The individuals
in the CG were recruited from children’s care clinic of the hospital and matched to the CFG for
age and sex, with a body mass index (BMI) in the ideal range and the absence of CF [17]. The fol-
lowing were the exclusion criteria for the CG: fever, trauma, diseases (celiac, respiratory, inflam-
matory, intestinal, rheumatic, psychiatric, degenerative, cardiovascular, diabetes mellitus, renal,
primary or secondary immunodeficiency and glucose/lactose intolerance) and use of antibiotics,
hormones, non-hormonal anti-inflammatory drugs, proton pump inhibitors, oral, inhaled and
intravenous corticosteroids, ranitidine hydrochloride, immunosuppressants and antihistamines
30 days prior to the data collection. The exclusion criteria for the CFG were the same as those for
the CG, except for the use of antibiotics. Patients taking antibiotics (colimycin, azithromycin,
tobramycin, cefuroxime, ciprofloxacin, oxacillin and ceftazidime) for the treatment of lung dis-
ease were admitted to the study. Daily supplementation as part of the protocol was taken into
account and supplement intake was determined on the basis of patient reports. The hospital
medical protocol prescribed the following supplements: SourceCF1 vitamin supplement (Eur-
and Pharmaceuticals, Huntsville, AL, USA) for those aged 1 year to< 4 years, 2 mL/day;
ADEK1 (Axcan Pharma, Birmingham, AL, USA) at a dose of one tablet/day for those aged 4
to< 10 years and two tablets/day for those aged 10 years [18]; CREON1 (Solvay Pharmaceu-
ticals, GmbH, Germany) for older children and adults, who require 500 to 4000 lipase units per
gram of fat ingested (mean = 1800 lipase units/g of fat) [19].
Assessment of clinical characteristics, BMI, lung function and disease
severity
Data on age, sex, date of birth, date of diagnosis of CF, colonization, antibiotic treatment and
mutation were collected from the patients’ medical records. Information on breastfeeding, the
use of an infant formula, type of delivery and the introduction of solid foods was based on
parental reports. Anthropometric data (height and weight) were collected using the method
described by Pereira [17]. BMI was classified based on the World Health Organization criteria
[20] using the Anthro and AnthroPlus programs (WHO, Geneva, Switzerland). Bacteriological
findings and lung function [assessed based on forced expiratory volume in one second
(FEV1)] were determined as described by Pereira [17]. Disease severity was determined based
on the Shwachman-Kulczycki (S-K) score [17].
Analysis of intestinal inflammation
For the analysis of fecal calprotectin, feces were collected in plastic containers and delivered
directly to the hospital. Intestinal inflammation was assessed based on fecal calprotectin,
which was measured using the RIDASCREEN1 Calprotectin (R-biopharm-AG) immunoen-
zyme test. Samples with a calprotectin concentration of 0 to 50 µg/g were considered normal,
values between 50 to 100 µg/g were considered intermediate and values higher than 100 µg/g
were considered indicative of intestinal inflammation [21].
Fluorescence in situ hybridization
A plastic straw measuring 4 cm in length and 3 mm in diameter was introduced 4 to 10 mm
into the feces for the collection of the sample, which was placed in a 50-mL Falcon, fixed with
30 mL of Carnoy’s solution composed of ethanol, glacial acetic acid and chloroform (6/6/1,
respectively) (Dinaˆmica Quı´mica Contemporaˆnea Ltda1) for 24 hours at room temperature
and then kept refrigerated at 4˚C until analysis [22].
Intestinal microbiota composition in patients with cystic fibrosis
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Fecal samples fixed in Carnoy’s solution were embedded in paraffin, cut longitudinally into 4-
µm sections, placed on SuperFrost slides (Thermo Scientific, Italy) and dewaxed with xylene and
ethanol (VWR Chemicals, United Kingdom). The samples were then incubated with a hybridiza-
tion solution (20 Mm Tris-HCL, 0.9 M NaCL, 0.1% SDS and 1% formamide at pH 7.4) with 100
ng of EUB mix of positive control oligonucleotide probes (EUB I, EUB II and EUB III) [22]. The
slides were incubated with hybridization buffer with 25 ng of their respective FISH probes for 45
min at 50 ºC, visualized and quantified using a Nikon 80i Eclipse epifluorescence microscope
with a Nikon DS-U2 color camera and the NIS-Element imaging software (Nikon, Tokyo,
Japan) [22]. Bacteria with uneven distribution or a low overall concentration were enumerated
within areas larger than 100 x 100 μm in whole microscopic fields or on the total surface of the
fecal cylinder. All counts were performed at a magnification of 1000 times. The conversion of
numbers within microscopic areas defined for bacterial concentrations per milliliter was based
on the calculation that a sample of 10 μL with a cell concentration of 107 cells/mL has an average
of 40 cells per field [22]. The samples were analyzed using the Eub338 mix probe conjugated
with fluorescein isothiocyanate (FITC, green signal) at the 5’ end (positive control) [23] and a
species-specific probe was conjugated with a single fluorescent carbocyanine molecule (Cy3, red
signal). All probes were purchased from MWG Eurofins Operon (Ebersberg, Germany).
Statistical analysis
Data with non-Gaussian distribution (determined using the Shapiro-Wilk test) were submit-
ted to logarithmic normalization prior to the multiple linear regression analyzes. Differences
between the CG and CFG regarding the variables used for characterization were analyzed
using Student’s t-test, Mann-Whitney test and chi-square test when categorical. Associations
among antibiotic use, intestinal inflammation and intestinal microorganisms in the CG and
CF groups were evaluated using multiple linear regression analysis adjusted for sex and age.
Spearman’s rank correlation coefficients were calculated considering the CG and CFG sepa-
rately to determine correlations among BMI, intestinal microorganisms and intestinal inflam-
mation. Statistical analysis was performed with the aid of the SPSS program, version 16.0 for
WindowsTM, with a p-value< 0.05 considered indicative of statistical significance.
Results
Demographic characteristics, clinical markers, intestinal inflammation and
intestinal microbiota
The participants were matched for sex and age, with no difference between the CG and CFG
groups (p> 0.05). However, the CFnAB group was composed of younger patients compared
to the other groups (Table 1). Delivery was by cesarean birth in the majority of the CFG
(73.7%) and vaginal birth in the majority of the CG (52.9%). Based on the supplementation
protocols, only one patient in the CFG did not supplement with pancreatic enzymes during
the study. Most patients were exclusively breastfed for less than six months (CG: 76.5%; CFG:
73.7%), which explains the frequent use of infant formulas (around 70% in both groups) and
the introduction of solid foods before six months of age (Table 1). No significant difference
was found between the CG and CFG regarding BMI, which suggests that CF does not affect
nutritional status (p = 0.186) (Table 1). In the stratified CFG, however, the CFnAB group had
a higher mean BMI compared to the CFAB group (17.32 ± 2.19 kg/m vs. 15.03 ± 0.92 kg/m,
p = 0.011), despite being composed mainly of younger patients (Table 1). The majority of
patients with CF had the Phe508del mutation (ΔF508) (68.4%); one patient did not have this
mutation and the remaining patients were not diagnosed during the study (Table 1). The
Intestinal microbiota composition in patients with cystic fibrosis
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disease severity score and lung function in the CFG were classified as excellent (88.57 points)
and good (80.67%), respectively. About 40% of the patients in the CFG had pulmonary coloni-
zation, 15.8% of whom were colonized by P. aeruginosa (Table 1) and about 25% were colo-
nized by Staphylococcus aureus and Burkholderia cepacia. These results are in line with the fact
that about 50% were using antibiotics (colimicin, azithromycin, tobramycin, cefuroxime, cip-
rofloxacin, oxacillin, ceftazidime) during the study (Table 1).
Fecal calprotectin (marker of intestinal inflammation) was significantly higher in CFG
(median: 40.80 µg/g, IQR: 19.80–87.10 µg/g, p = 0.017) and CFAB group (median: 62.95 µg/g,
IQR: 23.80–129.10 µg/g, p = 0.008) compared to the CG (median: 20.15 µg/g, IQR: 16.20–
31.00) (Tables 2 and 3). Bacteroides, Firmicutes, E. rectale and F. prausnitzii were significantly
lower (p< 0.05) in the CFG compared to the CG, whereas C. difficile, Escherichia coli (E. coli)
Table 1. Demographic and clinical markers of the control group (CG), cystic fibrosis group CFG), cystic fibrosis antibiotic therapy (CFAB) and cystic fibrosis
absence of antibiotic therapy (CFnAB).
Variables CG
(n = 17)
CFG
(n = 19)
p-value4 CFAB
(n = 10)
CFnAB
(n = 9)
p-value5
Age1,€ 3.00 (0.6–7.0) 4.00 (1.1–9.5) 0.552 6.00 (3.2–10.0) 1.50 (0.8–7.0) 0.447
Sex n (%)2,£ Male 11 (64.7) 10 (52.6) 0.317 03 (30.0) 07 (77.8) 0.051
Female 06 (35.3) 09 (47.4) 07 (70.0) 02 (22.2) Fisher
Type of delivery n (%)2,£ Vaginal 09 (52.9) 05 (26.3) 0.237 02 (20.0) 03 (33.3) 0.628
Cesarean 07 (41.2) 14 (73.7) 08 (80.0) 06 (66.7)
Breastfeeding n (%)2,£ < 6 months 13 (76.5) 14 (73.7) 0.003 07 (70.0) 07 (77.8) 0.701
 6 months 04 (23.5) 05 (26.3) 03 (30.0) 02 (22.2)
Infant formula n (%)2,£ No 05 (29.4) 05 (26.3) 0.836 03 (30.0) 02 (22.2) 0.701
Yes 12 (70.6) 14 (73.7) 07 (70.0) 07 (77.8)
Starting solid foods n (%)2,£ < 6 months 06 (35.3) 11 (57.9) 0.175 06 (60.0) 05 (55.6) 0.845
 6 months 11 (64.7) 08 (42.1) 04 (40.0) 04 (44.4)
BMI (kg/m)3,¥ 17.07 ± 1.38 16.17 ± 2.01 0.186 15.03 ± 0.92 17.32 ± 2.19 0.011
Mutation n (%)2 Homozygous Phe508del - 06 (31.6) - 04 (40.0) 02 (22.2) -
Heterozygous Phe508del - 07 (36.8) - 04 (40.0) 03 (33.3) -
Others 01 (5.3) - 01 (10.0) - -
No results - 01 (10.0) 04 (44.4) -
S-K score (points) - 88.57 ± 10.88 - 87.50 ± 9.35 89.38 ± 12.37 0.762
FEV1 (%)
2 - 80.67 ± 22.00 - 71.07 ± 25.19 93.48 ± 8.34 0.175
Lung colonization, n (%)2 Negative - 07 (36.8) - 01 (10.0) 06 (66.7) -
P. aeruginosa - 03 (15.8) - 03 (30.0) - -
Others - 05 (26.3) - 03 (30.0) 02 (22.2) -
No results 04 (21.1) 03 (30.0) 01 (11.1) -
Antibiotic therapy, n (%)2 No 17 (100) 09 (47.4) - - 09 (47.4) -
Yes - 10 (52.6) - 10 (52.6) - -
BMI: Body mass index; Shwachman-Kulczychi score: S-K escore. FEV1: Forced Expiratory Volume in the First Second. P. aeruginosa: Pseudomonas aeruginosa.
1Values in median and interquartile interval.
2Values in frequency and percentage.
3Values in mean and standard desviation.
€Performed Mann Whitney test.
£Performed chi-square test.
¥Performed Student’s t-test.
p-value4: CG versus CFG.
p value5: CFAB versus CFnAB. Significance p-value < 0.05.
https://doi.org/10.1371/journal.pone.0198457.t001
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and P. aeruginosa were significantly higher in the CFG (p< 0.05) (Tables 2 and 3). In the com-
parison of the two CF groups, only Bifidobacterium was significantly lower in the CFAB group
compared to the CFnAB group (sex and age adjusted analyses, p = 0.015) (Tables 2 and 4).
Associations between the use of antibiotics and both fecal calprotectin and
intestinal microorganisms
In the multiple linear regression analysis of the use of antibiotics adjusted for sex and age, fecal
calprotectin was significantly higher in the CFAB group (median: 62.95 μg/g feces, IQR:
21.80–136.63) compared to the CG (median: 20.15 μg/g feces, IQR: 16.20–31.00, p = 0.007)
(Tables 2 and 3), whereas no significant difference was found between the CFAB and CFnAB
groups (sex and age adjusted analyses, p = 0.181) (Tables 2, 3 and 4).
With regard to intestinal microorganisms, E. rectale and Firmicutes were significantly
higher in the GC compared to both the CFAB (E. rectale: p = 0.027; Firmicutes: p = 0.002) and
CFnAB (E. rectale: p = 0.003; Firmicutes: p = 0.004) groups, with no significant difference
between the two CF groups (Tables 2 and 3). Bifidobacterium was significantly lower in the CG
compared to the CFAB group (p = 0.011), but no significant difference was found in compari-
son to the CFnAB group (p = 1.000) (Tables 2 and 3). Bifidobacterium was the only microor-
ganism analyzed that was significantly lower in the CFAB group than the CFnAB group
(p = 0.010) (Tables 2 and 4). C. difficile and P. aeruginosa were lower in the CG compared to
both the CFAB (C. difficile: p = 0.001; P. aeruginosa: p = 0.001) and CFnAB (C. difficile:
p = 0.033; P. aeruginosa: p< 0.001) groups, with no significant difference between the two CF
groups (Tables 2–4).
Correlations between intestinal microorganisms and both BMI and fecal
calprotectin
A positive correlation was found between BMI and Bifidobacterium in the CFG (CFG:
rho = 0.658, p = 0.003; CG: rho = 0.372, p = 0.234) (Fig 1C), whereas no significant correlations
Table 2. Intestinal inflammation and intestinal microbiota of the control group (CG), cystic fibrosis group CFG), cystic fibrosis antibiotic therapy (CFAB-group)
and cystic fibrosis absence of antibiotic therapy (CFnAB-group).
Variables CG
(n = 17)
CFG
(n = 19)
CFAB
(n = 10)
CFnAB
(n = 9)
Intestinal inflammatory markers#
Fecal calprotectin (µg/g feces) 20.15 (16.20–31.00) 40.80 (19.80–87.10) 62.95 (23.80–129.10) 29.70 (10.40–52.20)
Intestinal microbiota#
Bacteroides (×109/mL feces) 28.30 (19.30–38.00) 15.70 (1.10–24.65) 2.92 (0.00–24.30) 20.00 (2.83–25.00)
Bifidobacterium (×109/mL feces) 20.30 (14.65–23.15) 13.00 (5.52–21.20) 5.51 (0.60–17.00) 20.70 (13.00–22.30)
Veillonella (×109/mL feces) 0.70 (0.00–11.35) 1.00 (0.00–4.39) 0.87 (0.00–1,77) 1.00 (0.00–7.00)
Firmicutes (×109/mL feces) 9.33 (1.55–12.17) 0.97 (0.77–1.57) 0.98 (0.60–1.53) 0.97 (0.77–1.63)
Eubacterium rectale (×109/mL feces) 21.00 (16.00–23.00) 10.70 (3.74–15.15) 12.5 (1.17–18.00) 10.30 (6.30–13.30)
Clostridium difficile (×109/ml feces) 0.20 (0.13–0.44) 0.50 (0.34–1.02) 0.54 (0.47–1,07) 0.50 (0.30–0.93)
Lactobacillus paracasei (×109/mL feces) 3.17 (2.02–8.47) 2.37 (1.79–5.74) 2.07 (1.40–5.00) 2.77 (2.27–6.47)
Faecalibacterium prausnitzii (×109/mL feces) 14.00 (3.92–27.65) 1.00 (0.17–11.50) 0.79 (0.00–4.43) 1.90 (0.33–18.00)
Escherichia coli (×109/mL feces) 0.67 (0.40–1.60) 1.47 (1.02–2.67) 1.79 (1.00–2.80) 1.37 (1.27–2.50)
Pseudomonas aeruginosa (×109/mL feces) 0.23 (0.15–0.53) 1.13 (0.87–3.92) 0.95 (0.70–1.93) 2.27 (1.10–5.00)
#Values presented in median and interquartile interval. Significance values of the comparisons between CG versus CF groups (CF, CFAB and CFnAB) and CFAB versus
CFnAB were represented by the crude “p” values of the multiple linear regression analysis (95% confidence interval) in Tables 3 and 4.
https://doi.org/10.1371/journal.pone.0198457.t002
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were found between BMI and other microorganisms (Fig 1 and S2 and S4 Tables). Negative
correlations were found between fecal calprotectin and both F. prausnitzii (CFG: rho = -0.478,
p = 0.039; CG: rho = -0.014, p = 0.964) (Fig 2C) and L. paracasei (CFG: rho = -0.504, p = 0.028;
CG = rho = -0.393, p = 0.184) (Fig 2D), whereas no significant correlations were found for
other microorganisms. A positive correlation was found between Bacteroides and L. paracasei
(CFG: rho = 0.503, p = 0.028; CG: rho = -0.184, p = 0.480) (supplementary material) and a neg-
ative correlation was found between Veillonella and E. rectale in the CFG (CFG: rho =,
p = 0.027; CG: rho = 0.078, p = 0.766) (S1 and S3 Tables).
Discussion
The literature reports intestinal abnormalities in the microbiota of patients with CF [6, 12, 24].
However, it is unclear whether this altered microbiota is the consequence of the disease or
antibiotic therapy and the implications of these changes remain unknown. The present study
shows a different pattern of bacterial species.
Table 3. Multiple linear regression analysis between control group (CG, n = 17) and cystic fibrosis group (CFG, n = 19), between CG (n = 17) and cystic fibrosis anti-
biotic therapy (CFAB-group), and between CG and cystic fibrosis absence of antibiotic therapy (CFnAB-group).
Variables Cystic fibrosis group (n = 19) CFAB (n = 10) CFnAB (n = 9)
Crude
β 0
coef.
p-value Adjusted β 1
coef.
p-value Crude
β 0
coef.
p-value Adjusted β 1
coef.
p-
value
Crude
β 0
coef.
p-value Adjusted β 1
coef.
p-value
Intestinal inflammatory markers#
Fecal calprotectin (µg/g
feces)
-0.384 0.030 -0.377 0.017 0.545 0.007 0.543 0.008 0.310 0.161 0.367 0.064
Intestinal microbiota#
Bacteroides (×109/mL
feces)
0.435 0.021 0.430 0.024 -0.495 0.027 -0.479 0.051 -0.426 0.048 -0.530 0.015
Bifidobacterium (×109/mL
feces)
0.296 0.095 0.275 0.131 -0.529 0.008 -0.531 0.018 0.008 0.969 -0.008 0.968
Veillonella
(×109/mL feces)
0.028 0.895 0.031 0.881 -0.087 0.733 -0.143 0.591 0.046 0.862 0.062 0.815
Firmicutes
(×109/mL feces)
0.633 <0.001 0.573 <0.001 -0.622 0.001 -0.476 0.002 -0.522 0.009 -0.549 0.001
Eubacterium rectale
(×109/mL feces)
0.364 0.041 0.383 0.034 -0.311 0.130 -0.299 0.171 -0.437 0.033 -0.490 0.026
Clostridium difficile
(×109/mL feces)
-0.384 0.027 -0.419 0.018 0.343 0.094 0.440 0.048 0.379 0.075 0.347 0.104
Lactobacillus paracasei
(×109/mL feces)
0.108 0.543 0.130 0.470 -0.184 0.378 -0.340 0.096 -0.020 0.924 -0.008 0.972
Faecalibacterium
prausnitzii
(×109/mL feces)
0.484 0.009 0.592 0.001 -0.592 0.005 -0,737 0.001 -0.383 0.087 -0.494 0.020
Escherichia coli (×109/mL
feces)
-0.452 0.006 -0.492 0.002 0.472 0.013 0.570 0.004 0.395 0.046 0.318 0.049
Pseudomonas aeruginosa
(×109/mL feces)
-0.727 <0.001 -0.728 <0.001 0.686 <0.001 0.607 0.001 0.785 <0.001 0.817 <0.001
β coef.: beta coefficient; β 0 coefficient: crude values; β 1 coefficient: values adjusted for confounding variables (sex and age).
# Values were normalized by log10 transformation.
“p-value” values were derived from the multiple linear regression analysis (95% confidence interval).
Boldface data indicate statistical significance (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0198457.t003
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The patients in the CFG had a similar BMI to the volunteers in the CG as well as adequate
lung function and an “excellent” disease severity score ( 86 points), although the majority
had the ΔF508 mutation, which is associated with the impairment of lung function and a con-
sequent worsening of nutritional status [25]. Pulmonary colonization by bacteria was found in
about 40% of the CFG. Moreover, one of the patients did not present pulmonary colonization
by P. aeruginosa at the collection time, but the bacterium was present in a large amount in the
intestinal microbiota. About three months after the study, the patient exhibited pulmonary
colonization by P. aeruginosa, which suggests that intestinal colonization may precede pulmo-
nary colonization [26]. However, longitudinal studies are needed to confirm this assumption.
The positive correlation found between BMI and Bifidobacterium in the CFG shows that an
improvement in nutritional status may be related to an increase of Bifidobacterium, which,
together with Faecalibacterium and E. rectale, is regarded as a marker of healthy intestinal
microbiota [15, 27]. Decreased quantities of these bacteria can affect the nutrition of entero-
cytes and, consequently, the maintenance of intestinal health [27, 28]. After weaning, Bifido-
bacterium gradually decreases and Bacteroides and Eubacterium become predominant, but it is
still considered a determinant of adult intestinal health [27]. Bifidobacterium was the only
microorganism that was significantly decreased in the CFAB group compared to the CFnAB
group, which may be related to the use of antibiotics.
With regard to breastfeeding, approximately 70% of both groups (CG and CFG) were
exclusively breastfed for less than six months and the CFG had lower values of the phylum Fir-
micutes. Lactate-producing bacteria, such as Lactobacillus, and those that use lactate, such as
bacteria belonging to the genera Veillonella and Faecalibacterium and the phylum Firmicutes,
provide the host with important short-chain fatty acid metabolites, which are related to protec-
tion against intestinal inflammation [6, 29]. The intestinal microbiome develops throughout
childhood, during which the assemblage is characterized by an increase in colonization by Bifi-
dobacteria and microorganisms belonging to the phyla Firmicutes and Bacteroidetes as well as
Table 4. Multiple linear regression analysis between cystic fibrosis antibiotic therapy (CFAB-group, n = 10) and cystic fibrosis absence of antibiotic therapy
(CFnAB-group, n = 9).
Variables Crude
β 0 coef.
p-value Adjusted
β 1 coef.
p-value
Intestinal inflammatory markers #
Fecal calprotectin (µg/g feces) -0.321 0.181 -0.223 0.320
Intestinal microbiota #
Bacteroides (×109/mL feces) 0.076 0.796 -0.032 0.932
Bifidobacterium (×109/mL feces) 0.532 0.028 0.725 0.015
Veillonella (×109/mL feces) 0.153 0.617 0.368 0.284
Firmicutes (×109/mL feces) 0.271 0.276 0.234 0.405
Eubacterium rectale (×109/mL feces) -0.013 0.962 -0.160 0.656
Clostridium difficile (×109/mL feces) 0.108 0.669 -0.019 0.948
Lactobacillus paracasei (×109/mL feces) 0.188 0.454 0.185 0.543
Faecalibacterium prausnitzii (×109/mL feces) 0.224 0.442 0.417 0.119
Escherichia coli (×109/mL feces) -0.138 0.572 -0.169 0.544
Pseudomonas aeruginosa (×109/mL feces) 0.291 0.241 0.375 0.202
β coef.: beta coefficient; β 0 coefficient: crude values; β 1 coefficient: values adjusted for confounding variables (sex and age).
#Values were normalized by log10 transformation.
“p-values” were derived from the multiple linear regression analysis (95% confidence interval).
Boldface data indicate statistical significance (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0198457.t004
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a reduction in Enterobacteria. Thus, any alteration in this colonization process leads to a
change in the composition of the microbiota [30].
Fecal calprotectin is considered a good marker of intestinal inflammation [31] and was
increased in the CFG (approximately 47% of the group had concentrations higher than 50 µg/
g of feces). This is in agreement with data described in the literature [6, 12]. The negative cor-
relation between fecal calprotectin and both F. prausnitzii and L. paracasei suggest that intesti-
nal inflammation may be related to a reduction in these bacteria. F. prausnitzii is a butyrate-
producing bacterium and the decrease in the production of this substance can exert an influ-
ence on both the nutritional status of enterocytes and luminal pH, consequently affecting the
maintenance of intestinal health [6]. Lactobacillus spp. are lactic acid-producing bacteria,
which is reported to be associated with the prevention of respiratory infections [32]. In the
analysis of the association between fecal calprotectin and the use of antibiotics, the influence of
antibiotic therapy on the development of intestinal inflammation in CF was not clear.
Although a difference was found between the CF groups, it was non-significant, which may be
a consequence of the sample size.
In the present study, butyrate-producing (E. rectale and F. prausnitzii), lactic acid-produc-
ing (L. paracasei and Bifidobacterium spp.) and acetate-producing (Bacteroides) microorgan-
isms were significantly lower and E. coli, C. difficile and P. aeruginosa were higher in the CFG
Fig 1. Correlation between body mass index (BMI) and intestinal microorganisms.Cystic fibrosis group (CFG), Control group (CG).p<0.05. BMI: Body mass
index. CFG: Cystic fibrosis group. CG: Control group.
https://doi.org/10.1371/journal.pone.0198457.g001
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compared to the CG, which is in agreement with data reported in the literature [6, 12, 27]. In
contrast, a previous study found no difference regarding Veillonella bacteria in the patients
with cystic fibrosis [33].
The negative correlation between Veillonella and E. rectale and the positive correlation
between Bacteroides and L. paracasei demonstrate a relationship among these
microorganisms.
The microorganisms Bacteroides, E. rectale, F. prausnitzii, Bifidobacterium and Firmicutes
were significantly lower in the CFAB group compared to the CG, whereas E. coli, C. difficile
and P. aeruginosa were significantly higher in the CFAB group compared to the CG. It should
be noted that these changes in the intestinal microbiota were also found in the CFnAB group.
Burk (2017) [24] found alterations in the intestinal microbiota of adults with CF, with an
increase in the phylum Firmicutes and a decrease in Bacteriodes, which differs from the present
findings. In contrast, Bruzzese (2014) [6] found similar results to those of the present investiga-
tion in a study involving children with CF. This difference may be due to the methods
employed as well as the difference in age, which consequently exerts an influence on the com-
position of the intestinal microbiota.
As previously reported in a study by Hoffman (2014) [34], E. coli was significantly increased
in the CFG. In a study involving patients with CF aged 10 to 22 years, Miragoli (2017) [12]
found an increase in E. coli in the group with CF, but the difference was non-significant in
comparison to the control group. The increase in E. coli has been related to dysbiosis and the
abundance of E. coli in patients with CF may be due to the decreased motility and/or
Fig 2. Correlation between fecal calprotectin and intestinal microorganisms in cystic fibrosis group (CFC) and control group (CG).  p<0.05. CFG: Cystic fibrosis
group. CG: Control group. Spearman’s correlation, p< 0.05.
https://doi.org/10.1371/journal.pone.0198457.g002
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accumulation of mucus [35]. Evidence suggests that changes in the intestinal lumen during an
inflammatory process may increase the ability of E. coli to colonize the intestinal mucosa and
induce further inflammation [34]. Hoffman (2017) [34] suggests that E. coli may serve as a
marker and cause of gastrointestinal tract dysfunction and disease in this population.
C. difficile is considered the major entero-pathogen of antibiotic-associated diarrhea and is
responsible for cases of pseudomembranous colitis [36, 37]. Indeed, this bacterium was found
to be increased in the CFG and CFAB group in the present study.
P. aeruginosa is considered the most aggressive bacterium with regard to pulmonary func-
tion in patients with CF. However, the occurrence and influence of this bacterium in the intes-
tinal microbiota of this population has not previously been studied. One study found that P.
aeruginosa was the most frequent species identified in the feces of patients with irritable bowel
syndrome and may be involved in the pathophysiology of the disease [38], indicating that it
may also be related to intestinal dysbiosis. The increase in P. aeruginosa in the intestinal micro-
biota and the fact that it preceded pulmonary colonization should be studied further to enable
a better understanding of the mechanisms involved as well as the harm that it can cause.
The microorganisms evaluated herein were selected based on their influence on the mainte-
nance of intestinal health and the relationship with CF reported in the literature [6, 8, 12, 34].
Therefore, the failure to analyze the microbiota population as a whole should be considered a
limitation of the present study. Other limitations are cross-sectional design, which does not
enable inferences regarding cause and effect, and the small sample size. However, the results of
the present study confirm the presence of intestinal inflammation in patients with CF and sug-
gest that the disease may be related to changes in the colonization of some microorganisms.
The frequent use of antibiotics does not appear to be closely related to the change in intestinal
microbiota, but further studies are needed to reach such conclusions.
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